QC
VKTX icon

Quent Capital’s Viking Therapeutics VKTX Stock Holding History

Quent Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11K Sell
54
-66
-55% -$2.13K ﹤0.01% 1469
2026
Q1 		$3.9K Sell
120
-15
-11% -$482 ﹤0.01% 1314
2025
Q4 		$4.75K Buy
135
+43
+47% +$1.52K ﹤0.01% 1282
2025
Q3 		$2.42K Buy
+92
New +$2.75K ﹤0.01% 1239
2025
Q2 		– Sell
-51
Closed -$1.23K – 1209
2025
Q1 		$1.23K Hold
51
– – ﹤0.01% 1188
2024
Q4 		$2.05K Buy
51
+1
+2% +$57 ﹤0.01% 1169
2024
Q3 		$3.17K Buy
+50
New +$2.93K ﹤0.01% 1176

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Quent Capital's VKTX Position: Q2 2026 in Review

Quent Capital reduced its Viking Therapeutics (VKTX) stake by 55% in Q2 2026, selling an estimated $2.13K and leaving 54 shares worth $2.11K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Quent Capital first reported a position in VKTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.75K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Quent Capital held 54 shares of Viking Therapeutics worth $2.11K as of Q2 2026.
  • Quent Capital sold 66 Viking Therapeutics shares in Q2 2026, an estimated $2.13K.
  • Viking Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1469 holding.
  • Quent Capital first reported a position in Viking Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Quent Capital's Viking Therapeutics position peaked at $4.75K in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.